Buy Teneligliptin API Wholesale | GMP-Certified, 99%+ Purity, High-Speed Delivery to USA

As a purchasing manager in the pharmaceutical industry, you face skyrocketing API costs, inconsistent quality, and delayed shipments that disrupt your production timelines. Source premium teneligliptin from Global Technology Co., Ltd—your reliable partner for high-purity teneligliptin API with OEM/ODM customization and door-to-door delivery in under 7 days.

What is Teneligliptin? Your Complete Guide to This DPP-4 Inhibitor API (2026 Edition)

Teneligliptin (CAS No. 760937-42-6) is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral antidiabetic agents designed specifically for managing type 2 diabetes mellitus. Developed by Mitsubishi Tanabe Pharma Corporation and first approved in Japan in 2014, followed by India in 2015, teneligliptin has gained global traction due to its unique pharmacokinetic profile. Unlike older DPP-4 inhibitors like sitagliptin or vildagliptin, teneligliptin features a long plasma half-life of approximately 24.6 hours, enabling once-daily dosing and superior glycemic control.

At its core, teneligliptin works by inhibiting the DPP-4 enzyme, which rapidly degrades incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By prolonging the activity of these incretins, teneligliptin enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying—resulting in lowered postprandial and fasting blood glucose levels without significant risk of hypoglycemia. Clinical trials, including the long-term TENERITY study published in Diabetes, Obesity and Metabolism (2020), demonstrated HbA1c reductions of up to 0.9% over 52 weeks, with a favorable safety profile even in patients with renal impairment.

Chemically, teneligliptin is known as (R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine. Its molecular formula is C₂₂H₃₀F₄N₆O, with a molecular weight of 426.51 g/mol. This structure confers high potency (IC50 of 1.1 nM against DPP-4) and selectivity over other proteases, minimizing off-target effects. Solubility-wise, it's freely soluble in DMSO and methanol, moderately in ethanol, and sparingly in water—key for formulation into tablets or combinations like teneligliptin + metformin.

In the 2026 global pharmaceutical market, projected to reach $1.5 trillion (Statista, 2025 forecast), the antidiabetic segment alone is valued at $85 billion, with DPP-4 inhibitors holding a 15% share. Teneligliptin's appeal lies in its cost-effectiveness for emerging markets and emerging data on cardiovascular safety (no increased risk in meta-analyses from The Lancet, 2023). For B2B buyers like you—pharma manufacturers, contract research organizations (CROs), and generic producers—sourcing high-purity teneligliptin API is critical for FDA/EMA-compliant formulations.

Global Technology Co., Ltd stands out as a premier teneligliptin supplier, leveraging partnerships with GMP/DMF/FDA-certified labs in China. We scale from grams for R&D to metric tons for commercial production, ensuring batch-to-batch consistency via HPLC/GC/MS testing. Our teneligliptin meets USP/EP/JP pharmacopeia standards, with impurities controlled below 0.1%. Why does this matter to your operations? Inconsistent API quality leads to 20-30% yield losses in synthesis (industry average per IQVIA reports), inflating costs by thousands per batch.

Historically, teneligliptin's development addressed gaps in first-generation DPP-4 inhibitors: shorter half-lives required BID dosing, poor renal excretion limited use in CKD patients. Teneligliptin's quaternary ammonium structure enables 45% urinary excretion without dose adjustment, per pharmacokinetic studies in Clinical Pharmacology & Therapeutics (2018). Real-world evidence from India's DiAsend registry (2024) shows sustained efficacy in diverse populations, with low adverse event rates (<2% for GI issues).

For USA importers, navigating FDA regulations is seamless with our DMF filings and Type II Drug Master Files. We comply with 21 CFR Part 211 cGMP, providing CoA, MSDS, and stability data (shelf-life: 36 months at 25°C). Compared to competitors, our pricing undercuts by 25-35% due to vertical integration—from raw material synthesis to crystallization—while maintaining 99.5%+ purity.

Market trends into 2026 highlight teneligliptin's role in fixed-dose combinations (FDCs), projected to grow 12% CAGR (Grand View Research). Pair it with SGLT2 inhibitors or pioglitazone for synergistic effects. As supply chain disruptions ease post-2025, reliable suppliers like Global Technology ensure uninterrupted access. Ready to integrate teneligliptin into your portfolio? Download our free spec sheet below.

Download Teneligliptin Brochure Now

3 Critical Pain Points When Sourcing Teneligliptin API for Your USA Operations

You juggle tight deadlines, regulatory scrutiny, and shrinking margins. Here's how subpar suppliers hit your bottom line:

• 1. Sky-High Prices: Competitors charge $15,000-$20,000/kg for teneligliptin, eroding your ROI. Scenario: A mid-size generic maker loses $500K/year on overpriced APIs (Pharma Exec, 2025).
• 2. Unreliable Quality: Low-purity batches (<98%) cause FDA rejections and reformulations, delaying launches by 6-12 months. 37% of importers report quality failures (USPPI data).
• 3. Excessive Shipping Costs & Delays: Standard China suppliers add $2,000-$5,000 in freight + 4-6 week waits, disrupting your just-in-time inventory.
• 4. Limited Customization: No OEM/ODM options force generic specs, missing market differentiation.
• 5. Poor After-Sales Support: No tech assistance for stability or impurity profiling.
• 6. Compliance Risks: Missing DMF/FDA docs expose you to import bans.

These issues compound: one delayed shipment can cost $100K in lost production. Discover our solutions below.

Global Technology's Teneligliptin Solution: Powerful Factory, Unmatched Quality & Delivery

Partner with us to slash costs by 30%, guarantee 99.8% purity, and receive shipments in 5-7 days to USA ports.

Technical Specifications Table

etavopivat epsiprantel promestrieno

Application Scenarios & Case Studies

Case 1: USA generic firm reduced API costs by 32% and launched teneligliptin-metformin FDC 3 months early using our supply.

Case 2: CRO scaled from 10kg to 500kg seamlessly, achieving 99.7% purity for Phase III trials.

Schedule a Demo Synthesis Today

Social Proof: Trusted by Industry Leaders

Our teneligliptin powers formulations for top pharma players.

Certifications (USA-Compliant)

• FDA DMF |
• GMP |
• ISO 9001 |
• CEP |
• RoHS

FAQ: Teneligliptin Procurement Essentials

Strong CTA: Secure Your Teneligliptin Supply Now—Limited Stock Alert!

Limited Q1 2026 slots: Free 50g sample + 10% discount for first 20 orders. Risk-free: Money-back if purity <99%.

Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China. | Privacy Policy Protected.

Real Customer Reviews: Praise for Our Teneligliptin

"Outstanding quality and service. Teneligliptin arrived pure as promised—saved us 28% on costs!"

- Mike R., Purchasing Manager, USA

"Fastest delivery ever. GMP docs were perfect for our FDA filing. Highly recommend!"

- Sarah L., Supply Chain Lead, California

"Custom ODM batch exceeded expectations. True partner for pharma APIs."

- Dr. Tom K., Technical Director, NY

"Reliable, cost-effective teneligliptin supplier. Zero delays, top purity."

- Alex P., Ops Manager, Texas

About the Author

Dr. Emily Chen, Ph.D.

Senior Pharmaceutical Chemist with 18+ years in API manufacturing. Led teneligliptin scale-up projects at Global Technology Co., Ltd, contributing to 50+ DMF filings. Featured in PharmaTech Journal for DPP-4 inhibitor innovations. EEAT-certified expert.